Synapse - Paul Chapman

Search Within

Paul Chapman

Results (327)

Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: A retrospective, multicohort analysis

Journal Article

McQuade, J. L.; Daniel, C. R.; Hess, K. R.; Mak, C.; Wang, D. Y.; Rai, R. R.; Park, J. J.; Haydu, L. E.; Spencer, C.; Wongchenko, M.; more...
Lancet Oncology (2018)

Fulltext@MSK | Save

Peripheral blood clinical laboratory variables associated with outcomes following combination nivolumab and ipilimumab immunotherapy in melanoma

Journal Article

Rosner, S.; Kwong, E.; Shoushtari, A. N.; Friedman, C. F.; Betof, A. S.; Brady, M. S.; Coit, D. G.; Callahan, M. K.; Wolchok, J. D.; Chapman, P. B.; more...
Cancer Medicine (2018)

Fulltext@MSK | Save

Measuring toxic effects and time to treatment failure for nivolumab plus ipilimumab in melanoma

Journal Article

Shoushtari, A. N.; Friedman, C. F.; Navid-Azarbaijani, P.; Postow, M. A.; Callahan, M. K.; Momtaz, P.; Panageas, K. S.; Wolchok, J. D.; Chapman, P. B.
JAMA Oncology (2018)

Fulltext@MSK | Save

Dual MEK/AKT inhibition with trametinib and GSK2141795 does not yield clinical benefit in metastatic NRAS-mutant and wild-type melanoma

Journal Article

Algazi, A. P.; Esteve-Puig, R.; Nosrati, A.; Hinds, B.; Hobbs-Muthukumar, A.; Nandoskar, P.; Ortiz-Urda, S.; Chapman, P. B.; Daud, A.
Pigment Cell & Melanoma Research (2018)

Fulltext@MSK | Save

PTEN loss-of-function alterations are associated with intrinsic resistance to BRAF inhibitors in metastatic melanoma

Journal Article

Catalanotti, F.; Cheng, D. T.; Shoushtari, A. N.; Johnson, D. B.; Panageas, K. S.; Momtaz, P.; Higham, C.; Won, H. H.; Harding, J. J.; Merghoub, T.; more...
JCO Precision Oncology (2017)

Fulltext@MSK | Save

Overall survival (OS) analysis from an expanded access program (EAP) of nivolumab (NIVO) in combination with ipilimumab (IPI) in patients with advanced melanoma (MEL)

Meeting Abstract

Hogg, D.; Chapman, P. B.; Sznol, M.; Lao, C. D.; Gonzalez, R.; Daniels, G. A.; Smylie, M.; Kudchadkar, R. R.; Thompson, J. A.; Sharfman, W. H.; more...
Journal of Clinical Oncology (2017)

Fulltext@MSK | Save

Clinical benefit and toxicity of nivolumab plus ipilimumab in patients with advanced melanoma previously treated with checkpoint blockade inhibitors

Meeting Abstract

Friedman, C. F.; Wolchok, J. D.; Postow, M. A.; Shoushtari, A. N.; Callahan, M. K.; Momtaz, P.; Chapman, P. B.
Journal of Clinical Oncology (2017)

Fulltext@MSK | Save

Updated 5-y landmark analyses of phase 2 (BREAK-2) and phase 3 (BREAK-3) studies evaluating dabrafenib monotherapy in patients with BRAF V600-mutant melanoma

Meeting Abstract

Chapman, P. B.; Ascierto, P. A.; Schadendorf, D.; Grob, J. J.; Ribas, A.; Kiecker, F.; Dutriaux, C.; Demidov, L. V.; Lebbe, C.; Rutkowski, P.; more...
Journal of Clinical Oncology (2017)

Fulltext@MSK | Save

Clinical and morphologic characteristics of MEK inhibitor - Associated retinopathy: Differences from central serous chorioretinopathy

Journal Article

Francis, J. H.; Habib, L. A.; Abramson, D. H.; Yannuzzi, L. A.; Heinemann, M.; Gounder, M. M.; Grisham, R. N.; Postow, M. A.; Shoushtari, A. N.; Chi, P.; more...
Ophthalmology (2017)

Fulltext@MSK | Save

Four-month course of adjuvant dabrafenib in patients with surgically resected stage IIIC melanoma characterized by a BRAFV600E/K mutation

Journal Article

Momtaz, P.; Harding, J. J.; Ariyan, C.; Coit, D. G.; Merghoub, T.; Gasmi, B.; You, D.; Viale, A.; Panageas, K. S.; Samoila, A.; more...
Oncotarget (2017)

Fulltext@MSK | Save